Edammo
Edammo, Inc., a Fremont-based AI company, was acquired by Verseon International Corporation in October 2022.
Profile
Develops AI-driven solutions for small-data challenges in pharmaceutical research.
Edammo, Inc., a Fremont-based AI company, was acquired by Verseon International Corporation in October 2022. Founded with a focus on small-data AI technology, Edammo developed its proprietary Extreme AutoML platform, which outperformed industry benchmarks like Google AutoML in accuracy and speed. The acquisition aimed to enhance Verseon’s drug discovery platform, leveraging Edammo’s technology to address challenges in small-data scenarios prevalent in pharmaceutical research.
Post-acquisition, Edammo’s technology has been integrated into Verseon’s pipeline, which includes seven drug programs targeting conditions such as anticoagulation, diabetic retinopathy, hereditary angioedema, oncology, and metabolic disorders. Edammo’s CEO, Ed Ratner, emphasized the alignment of their mission with Verseon’s goal of developing critical new medicines. As of 2026, Edammo’s contributions are evident in Verseon’s advancements in neural network architectures, demonstrated in papers presented at the IEEE International Conference on Future Machine Learning and Data Science in November 2025. The company’s focus remains on leveraging AI to improve drug discovery efficiency and accuracy.
Who buys this
- Pharmaceutical companies
- Biotechnology firms
- Life sciences research institutions
- AI-driven drug discovery platforms
Strengths and what to watch
Strengths
- Proprietary Extreme AutoML platform outperforms industry benchmarks like Google AutoML.
- Specialized in handling small, sparse datasets common in novel drug development.
- Integrated into Verseon’s advanced drug discovery pipeline, enhancing its capabilities.
Watch for
- Dependence on Verseon’s strategic direction post-acquisition.
- Potential challenges in scaling technology across diverse pharmaceutical applications.
- Competition from other AI-driven drug discovery platforms.
Recent moves
- 7mo ago How Physics-based Modeling Can Help Solve the Challenges Facing the Pharmaceutical Industry
- 10mo ago Verseon CEO Adityo Prakash Discusses Transforming Drug Discovery to Find the Breakthrough Treatments of Tomorrow
- 10mo ago Verseon's Innovations in Neural Network Architectures Offer Superior Solutions for Life Sciences
Key Information
- Founded
- 1967
- Headquarters
- Fremont
Frequently Asked Questions
What is Edammo and what do they do?
Edammo develops AI-driven solutions for small-data challenges in pharmaceutical research. Acquired by Verseon in 2022, its Extreme AutoML platform outperforms benchmarks like Google AutoML. The technology enhances drug discovery, particularly in sparse datasets common in novel drug development. (47 words)
How does Edammo's Extreme AutoML compare to Google AutoML?
Edammo's Extreme AutoML platform demonstrated superior accuracy and speed versus Google AutoML in benchmarks. Specialized for small-data scenarios in pharma research, it addresses sparse datasets more effectively. This performance drove Verseon's acquisition to bolster their drug discovery pipeline. (45 words)
Why did Verseon acquire Edammo?
Verseon acquired Edammo in 2022 to integrate its small-data AI technology into drug discovery. The Extreme AutoML platform enhanced Verseon's capabilities for pharmaceutical research, particularly in handling sparse datasets. The alignment supported Verseon's seven active drug programs across multiple therapeutic areas. (48 words)
What are Edammo's key applications in drug discovery?
Edammo's AI solutions optimize pharmaceutical research for anticoagulation, diabetic retinopathy, hereditary angioedema, oncology, and metabolic disorders. Its technology improves efficiency in small-data scenarios prevalent in early-stage drug development. Post-acquisition, these applications expanded within Verseon's neural network architectures. (46 words)
What challenges does Edammo's technology solve in pharma?
Edammo addresses small, sparse datasets common in novel drug development where traditional AI struggles. Its Extreme AutoML platform provides superior accuracy in these scenarios, accelerating research. This capability is critical for Verseon's pipeline targeting complex conditions with limited initial data. (48 words)
How has Edammo contributed to Verseon's recent advancements?
Post-acquisition, Edammo's technology enhanced Verseon's neural network architectures, evidenced in IEEE Conference papers. It improved drug discovery efficiency, particularly for Verseon's seven active programs. The integration demonstrates measurable progress in handling pharmaceutical research's small-data challenges. (45 words)
Sources
- www.prnewswire.com — Details of Verseon’s acquisition of Edammo and its integration into Verseon’s drug discovery platform.
- www.edammoinc.com — Edammo’s mission and focus on AI-driven precision engineering for drug discovery.
- www.prnewswire.com — Verseon’s advancements in neural network architectures post-Edammo acquisition.
- www.verseon.com — Recent news on Verseon’s physics-based modeling and its impact on pharmaceutical challenges.